On the face of it, I wouldn’t get overly excited by the drop. However, I’ve been underwhelmed and wrong before. If you’ve got access to a synchrotron beamline that can shoot the material in-situ it might be a good experiment to try. Best of luck, Dave
Dr. David Hargreaves Associate Principal Scientist _____________________________________________________________________ AstraZeneca Discovery Sciences, Structure & Biophysics Dr David Hargreaves. OfficeR1-09/Lab FL54 AstraZeneca Darwin Building Unit 310 Cambridge Science Park Milton Road Cambridge CB4 0WG telephone: +441223223546 mobile: 07525 742054 David.Hargreaves @astrazeneca.com<mailto:[email protected]> Please consider the environment before printing this e-mail From: CCP4 bulletin board [mailto:[email protected]] On Behalf Of P Silva Sent: 05 January 2015 19:12 To: [email protected] Subject: [ccp4bb] Crystallization issue Hi everyone, Sorry for the non related crystallization question. In a crystallization screening (20ºC) I got in 70% of the drops some fibrils/gel (see figure below) which I do not know how to interpret. Has anyone got the same kind of behavior in crystallization screenings? It could be related with the stability of the protein (salt concentration, pH,...)? The buffer of the protein is 20mM Tris pH 7.5, 150mM NaCl. Thanks in advance ________________________________ AstraZeneca UK Limited is a company incorporated in England and Wales with registered number: 03674842 and a registered office at 2 Kingdom Street, London, W2 6BD. Confidentiality Notice: This message is private and may contain confidential, proprietary and legally privileged information. If you have received this message in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this message is not permitted and may be unlawful. Disclaimer: Email messages may be subject to delays, interception, non-delivery and unauthorised alterations. Therefore, information expressed in this message is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by an authorised representative independent of this message. No contractual relationship is created by this message by any person unless specifically indicated by agreement in writing other than email. Monitoring: AstraZeneca UK Limited may monitor email traffic data and content for the purposes of the prevention and detection of crime, ensuring the security of our computer systems and checking compliance with our Code of Conduct and policies.
